医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Bond Labs’ NDS Team to Visit Australia

2012年10月02日 PM11:00
このエントリーをはてなブックマークに追加


 

OMAHA, Neb.

Bond Laboratories, Inc. (OTCBB:BNLB) (“Bond Labs”), an international provider of innovative and proprietary nutritional supplements for health conscious consumers marketed primarily through its wholly owned operating division, NDS Nutrition Products (“NDS”), today announces that the Company’s NDS team will travel to Australia in early October. The NDS team, including Bond Labs, Inc. President and CEO, John Wilson, intends to spend a significant amount of time in Australia traveling to and meeting with each franchise owner in order to introduce NDS products.

“Australia is one of the largest sports nutrition markets in the world and a critical element in our plan to expand international distribution. This event truly marks an exciting opportunity and milestone in our overall growth strategy,” stated Mr. Wilson. “Our initial launch will focus on 3 of the more than 50 products currently marketed in the U.S.; Pump Fuel®, ACG3® and Cardio Cuts®. We anticipate aggressively adding additional products into the franchise distribution system as we ramp up our presence and brand awareness in this new market.”

“Our relationship with GNC® International allows us to further our growth strategy of increasing the number of retail outlets selling NDS products while continuing to introduce new products into the distribution system. GNC presently has over 1,600 international franchise stores in 56 different countries, and we believe that this is just the beginning of what we anticipate will be a huge opportunity to grow revenue and bolster our presence in the nutritional supplement industry,” concluded Mr. Wilson.

About Bond Labs

Bond Laboratories is a manufacturer of innovative nutritional supplements. The Company produces and markets products through its NDS Nutrition division. NDS’ products number over 50 brands of energy, sports and dietary supplements. These products are sold directly through specialty health and nutrition retailers, including top-selling products at GNC® franchises. Bond Labs is headquartered in Omaha, Nebraska. For more information, please visit http://www.bond-labs.com.

Forward-Looking Statement

Statements in this release that are forward looking involve known and unknown risks and uncertainties, which may cause the Company’s actual results in future periods to be materially different from any future performance that may be suggested in this news release. Such factors may include, but are not limited to: the ability to of the Company to continue to grow revenue; the Company’s ability to continue to achieve positive cash flow given the Company’s existing and anticipated operating and other costs; and the outcome of the Company’s pending litigation with the U.S. Department of Labor and our former President alleging violations of certain unlawful employment practices in connection with his separation from the Company. Many of these risks and uncertainties are beyond the Company’s control. Reference is made to the discussion of risk factors detailed in The Company’s filings with the Securities and Exchange Commission, including its reports on Form 10-K and 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the dates on which they are made.

CONTACT

Surety Financial Group, LLC
Bruce Weinstein, 410-833-0078

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表